Professional Analysts at Chardan Capital Reconfirmed their Buy rating for Amicus Therapeutics (NDAQ:FOLD). The Price Objective is Set to $16.50

Share with your friends


NewYork Amicus Therapeutics NDAQ:FOLD

Amicus Therapeutics (NDAQ:FOLD) Rating Reconfirmed

They currently have a $16.50 target price per share on Amicus Therapeutics (NDAQ:FOLD). Chardan Capital’s target would suggest a potential upside of 21.32 % from the company’s previous close. This was revealed in a report on 13 September.

NDAQ:FOLD is right now trading 1.81% higher at $13.52 as of 8:01 AM New York time. Amicus Therapeutics’s stock is 0% over the past 200 days. It has underperformed the S&P 500, which has gained 6.00% over the same time.

According to data compiled by Thomson Reuters, Amicus Therapeutics (NDAQ:FOLD)’s stock is covered by 7 equity analysts across the Street, with 0 analysts giving it a Sell rating, 5 a Buy rating, while 2 consider it a Hold. The 12-month consensus target price for the stock is $13, which reflects an downside potential of 3.85% over the current price.

FOLD Stock Chart

Institutional Ownership

Redmile Group Llc had the largest stake with ownership of 12.75M shares as of q2 2015 for 7.51% of the fund portfolio. Perceptive Advisors Llc is another quite bullish active investment manager who is possessing 14.12M shares of Amicus Therapeutics or 6.74% of their fund portfolio. Moreover, Venbio Select Advisor Llc have 4.79% of their fund portfolio invested in the company for 3.69M shares. The Quebec – Canada-based fund Sectoral Asset Management Inc disclosed it had acquired so far a stake worth about 3.05% of the active investment manager’s stock portfolio in Amicus Therapeutics. The California-based fund Palo Alto Investors Llc is also positive about the stock, possessing 4.19M shares or 2.44% of their fund portfolio.

Amicus Therapeutics (NDAQ:FOLD) Profile

Amicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Amicus Therapeutics (NDAQ:FOLD) traded up 1.81% on 13 September, hitting $13.52. A total of 11.51 million shares of the company’s stock traded hands. This is up from average of 2.78 million shares. Amicus Therapeutics has a 52 week low of $4.41 and a 52 week high of $14.36. The company has a market cap of $2.22 billion and a P/E ratio of 0.

Get the latest Amicus Therapeutics (NDAQ:FOLD) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.